Cereno Scientific Announces FDA-Approved Phase I PK Study of CS014 for PH-ILD Treatment Cereno Scientific has received approval to start a Phase I pharmacokinetic study for CS014, targeting pulmonary hypertension with innovative treatments aimed at enhancing patient life.

Cereno Scientific Announces FDA-Approved Phase I PK Study of CS014 for PH-ILD Treatment #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific Launches Phase I Study of CS014 for PH-ILD Treatment After FDA Approval Cereno Scientific has been granted approval for a Phase I pharmacokinetic study of CS014, in a significant step toward treating pulmonary hypertension-related conditions.

Cereno Scientific Launches Phase I Study of CS014 for PH-ILD Treatment After FDA Approval #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease Cereno Scientific is broadening its clinical focus for CS014 to target pulmonary hypertension linked to interstitial lung disease, addressing significant unmet medical needs.

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease #Sweden #Gothenburg #Pulmonary_Hypertension #Cereno_Scientific #CS014

Cereno Scientific Expands CS014 Focus to Treat Pulmonary Hypertension in Lung Disease Cereno Scientific is expanding the development of its treatment CS014 to address pulmonary hypertension related to interstitial lung disease, targeting a significant unmet medical need.

Cereno Scientific Expands CS014 Focus to Treat Pulmonary Hypertension in Lung Disease #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific's Innovative HDAC Inhibitor CS014 Shows Promise in Cardiopulmonary Diseases Cereno Scientific has unveiled its groundbreaking HDAC inhibitor CS014, demonstrating effective antithrombotic properties without bleeding risks, supporting potential cardiovascular applications.

Cereno Scientific's Innovative HDAC Inhibitor CS014 Shows Promise in Cardiopulmonary Diseases #Sweden #Gothenburg #Cardiovascular_Diseases #Cereno_Scientific #CS014

Cereno’s IPF drug clears Phase I, paving way for Phase II The company plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.

Armed with positive topline results from its Phase I trial, Cereno plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.

#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews

Cereno’s IPF drug clears Phase I, paving way for Phase II The company plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.

Armed with positive topline results from its Phase I trial, Cereno plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.

#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews